Shares of BSX rose 5.4% at $53.50 apiece in early-morning trading today. MassDevice’s MedTech 100, — which includes stocks of the world’s largest medical device companies — rose nearly 1%.
The pivotal ADVENT trial evaluated the nonthermal treatment for ablating heart tissue in patients with AFib. It marks the first randomized clinical trial directly comparing the efficacy and safety of Farapulse against standard-of-care ablation — either radiofrequency or cryoablation — for treating paroxysmal or intermittent AFib.
Boston Scientific presented findings at the annual meeting of the European So…